NCT03940352 2025-10-10
HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
Novartis
Phase 1 Terminated
Clinical Trials
8 trialsNCT05155709 2025-10-10
A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.
Novartis
Phase 1 Terminated
NCT05599932 2025-07-09
Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment
Novartis
Phase 1 Completed
NCT02890069 2023-01-11
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Novartis
Phase 1 Completed
NCT02601378 2022-09-29
A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.
Novartis
Phase 1 Terminated
NCT02143635 2021-05-21
Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt
Novartis
Phase 1 Completed
NCT02343172 2020-12-09
Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma
Novartis
Phase 1 Completed
NCT03760445 2020-01-09
HDM201 Added to CT in R/R or Newly Diagnosed AML
Novartis
Phase 1/2 Withdrawn